Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy.

ABSTRACT: The Stimulator of Interferon Genes (STING) pathway is a promising target for cancer immunotherapy. Despite recent advances, therapies targeting the STING pathway are often limited by routes of administration, suboptimal STING activation, or off-target toxicity. Here, we report a dendritic cell (DC)-targeted polymeric prodrug platform (polySTING) that is designed to optimize intracellular delivery of a diamidobenzimidazole (diABZI) small-molecule STING agonist while minimizing off-target toxicity after parenteral administration. PolySTING incorporates mannose targeting ligands as a comonomer, which facilitates its uptake in CD206⁺/mannose receptor⁺ professional antigen-presenting cells (APCs) in the tumor microenvironment (TME). The STING agonist is conjugated through

SUBMITTER: Nguyen DC 

PROVIDER: S-EPMC10979423 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature